Dipartimento di Medicina Interna, A.O. Fatebenefratelli e Oftalmico, Milano, Italy.
Am J Gastroenterol. 2013 Jul;108(7):1112-22. doi: 10.1038/ajg.2013.110. Epub 2013 Jun 4.
The occurrence of decompensation marks a crucial turning point in the course of cirrhosis. The purpose of this study was to assess the risk of mortality according to the clinical characteristics of first decompensation, considering also the impact of acute-on-chronic liver failure (AoCLF).
We conducted a prospective nationwide inception cohort study in Italy. Decompensation was defined by the presence of ascites, either overt or detected by ultrasonography (UD), gastroesophageal variceal bleeding (GEVB), and hepatic encephalopathy (HE). AoCLF was defined according to the Asian Pacific Association for the Study of the Liver criteria. Multivariable Cox proportional hazards regression was used to analyze the risk of failure (death or orthotopic liver transplantation (OLT)).
A total of 490 consecutive cirrhotic patients (314 males, mean age 60.9±12.6 years) fulfilled the study criteria. AoCLF was identified in 59 patients (12.0%). Among the remaining 431 patients, ascites were found in 330 patients (76.6%): in 257 (77.8%) as overt ascites and in 73 (22.2%) as UD ascites. GEVB was observed in 77 patients (17.9%) and HE in 30 patients (7.0%). After a median follow-up of 33 months, 24 patients underwent OLT and 125 died. The cumulative incidence of failure (death or OLT) after 1, 2, and 3 years was, respectively, 28, 53, and 62% in patients with AoCLF; 10, 18, and 25% in patients with UD ascites; 17, 31, and 41% in patients with overt ascites; and 8, 12, and 24% in patients with GEVB (P<0.0001).
AoCLF is responsible for a relevant proportion of first decompensation in cirrhotic patients and is associated with the poorest outcome. Patients with UD ascites do not have a negligible mortality rate and require clinical monitoring similar to that of patients with overt ascites.
失代偿的发生标志着肝硬化病程中的一个关键转折点。本研究旨在评估首次失代偿的临床特征所对应的死亡率风险,同时考虑到慢加急性肝衰竭(ACLF)的影响。
我们在意大利进行了一项前瞻性全国性发病队列研究。失代偿的定义为腹水的出现,无论是显性腹水还是超声检查(US)发现的腹水,胃食管静脉曲张出血(GEVB)和肝性脑病(HE)。ACLF 根据亚太肝病学会标准定义。多变量 Cox 比例风险回归用于分析失败(死亡或原位肝移植(OLT))的风险。
共有 490 例连续的肝硬化患者(314 名男性,平均年龄 60.9±12.6 岁)符合研究标准。59 例(12.0%)患者存在 ACLF。在其余 431 例患者中,330 例(76.6%)患者发现腹水:257 例(77.8%)为显性腹水,73 例(22.2%)为 US 发现的腹水。77 例(17.9%)患者出现 GEVB,30 例(7.0%)患者出现 HE。中位随访 33 个月后,24 例患者接受了 OLT,125 例患者死亡。ACLF 患者 1、2 和 3 年的累积失败(死亡或 OLT)发生率分别为 28%、53%和 62%;US 发现腹水的患者分别为 10%、18%和 25%;显性腹水的患者分别为 17%、31%和 41%;GEVB 的患者分别为 8%、12%和 24%(P<0.0001)。
ACLF 是肝硬化患者首次失代偿的一个重要原因,与最差的结局相关。US 发现腹水的患者死亡率不容忽视,需要与显性腹水的患者进行类似的临床监测。